[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
February 5, 2014

Patient-Centered and Practical Application of New High Cholesterol Guidelines to Prevent Cardiovascular Disease

Author Affiliations
  • 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota
  • 2Knowledge and Evaluation Research Unit, Division of Endocrinology, Mayo Clinic, Rochester, Minnesota
  • 3Knowledge and Evaluation Research Unit, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
JAMA. 2014;311(5):465-466. doi:10.1001/jama.2014.110

In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) published new guidelines for assessing cardiovascular disease (CVD) risk1 and for treatment of blood cholesterol to reduce CVD.2 These new guidelines replaced the Adult Treatment Panel III (ATP III) guidelines for the detection, evaluation, and treatment of high blood cholesterol3 that guided clinical practice for more than a decade. The new guidelines divert focus from lowering low-density lipoprotein (LDL) cholesterol levels to treating CVD risk and therefore are no longer pure cholesterol guidelines like the ATP III predecessor. The new guidelines also discourage the prescription of lipid-lowering medications, such as ezetimibe or niacin, that do not have proven effect on reducing CVD risk. These changes represent a major shift in preventive cardiology.

First Page Preview View Large
First page PDF preview
First page PDF preview
×